ReviewImmunology and allergy clinics of North America2022
Pathophysiology of Asthma-Chronic Obstructive Pulmonary Disease Overlap.
Review in Immunology and allergy clinics of North America, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 4 citations in OpenAlex.
- Association Between Composite Dietary Antioxidant Index and Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome: Evidence From a Large Cohort in the UK Biobank.Food science & nutrition · 2026Article
- Nicotinamide adenine dinucleotide phosphate oxidase 4 in lung disease: a review of its biology and therapeutic potential.Experimental biology and medicine (Maywood, N.J.) · 2026Review
- The miR-146a/Human mutation · 2026Article
- Targeted biologic therapies and advanced drug delivery approaches in asthma management: a clinical perspective.Inflammopharmacology · 2025Review
- Prospective, Open-Label, Observational, Multicenter, Single Arm, Post-Marketing Study in Asthmatic Patients for Evaluation of Safety and Effectiveness of Indacaterol/Mometasone DPI (PROMISING-SHIFT).Advances in respiratory medicine · 2025Observational
- Exploring the pathogenesis and clinical implications of asthma, chronic obstructive pulmonary disease (COPD), and asthma-COPD overlap (ACO): a narrative review.Frontiers in medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Asthma-chronic obstructive pulmonary disease (COPD) overlap (ACO) is a condition in which a person has clinical and biological features of both asthma and COPD. The pathophysiology behind the development of ACO is complex, with various inflammatory cells, cytokines, environmental factors, and architectural changes within the airways, all affecting a patient's clinical manifestation. A better understanding of the pathophysiologic mechanisms resulting in the development of ACO will help us to better identify potential drug targets and improve symptom burden and overall quality of life for patients living with ACO.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.